hen re-randomized to a maintenance treatment phase for up to 48 weeks.

About atopic dermatitis
Atopic dermatitisis a common, chronic, and flaring inflammatory skin disease, characterized by persistent itch and recurrent skin lesions.7,8,18It is the most common inflammatory skin disease, impacting almost four times more people than psoriasis.8,19It affects approximately 10 to 40 million people in the European Union, with up to 66% of adults suffering with a moderate-to-severe form of the condition.20,21

About the OLYMPIA clinical trial program22,23
The OLYMPIA program included two identically designed, pivotal phase III clinical trials which enrolled 560 patients – OLYMPIA 1 and OLYMPIA 2. This is the largest clinical trial program conducted in prurigo nodularis to date, and the only program to include a long-term extension study.

These global, randomized, double-blind, placebo-controlled phase III clinical trials assessed the efficacy and s
=*=*=*=*=*=
当前为第8/16页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页